Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | GAA | P10253 | 4/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.51 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | CA12 | O43570 | 3/20 | 0.46 |
| ▸ | CA2 | P00918 | 3/20 | 0.46 |
| ▸ | CA7 | P43166 | 3/20 | 0.46 |
| ▸ | CA9 | Q16790 | 3/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.46 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29943277 | 1.00 | ALDH1A1 (0.53) | ALDH1A1GAAKDM4EMAPTHSD17B10 | |
| SCHEMBL10424450 | 0.91 | ALDH1A1 (0.49) | ALDH1A1GAAKDM4EMAPTHSD17B10 | |
| SCHEMBL27523349 | 0.86 | GAA (0.50) | ALDH1A1GAAKDM4EMAPTHSD17B10 | |
| SCHEMBL4686032 | 0.86 | ALDH1A1 (0.46) | ALDH1A1GAAKDM4EMAPTHSD17B10 | |
| SCHEMBL1754056 | 0.86 | ALDH1A1 (0.46) | ALDH1A1GAAKDM4EMAPTHSD17B10 | |
| SCHEMBL365955 | 0.86 | CYP4A11 (0.49) | ALDH1A1GAAKDM4EMAPTHSD17B10 | |
| SCHEMBL5058622 | 0.86 | CA12 (0.61) | ALDH1A1GAAKDM4EMAPTHSD17B10 | |
| SCHEMBL603667 | 0.86 | ALDH1A1 (0.50) | ALDH1A1GAAKDM4EMAPTHSD17B10 | |
| SCHEMBL29775267 | 0.86 | ALDH1A1 (0.46) | ALDH1A1GAAKDM4EMAPTHSD17B10 | |
| SCHEMBL1636594 | 0.86 | ALDH1A1 (0.50) | ALDH1A1GAAKDM4EMAPTHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1814847-B1 | NOVEL METHOD FOR PREPARING 3-[5'-(3,4-BIS-HYDROXYMETHYL-BENZYLOXY)-2'- ETHYL-2-PROPYL-BIPHENYL-4-YL]-PENTA-3-OL | GALDERMA RES & DEV (FR) | 2011-01-12 | — | — | EP | claimed |
| US-7638657-B2 | Preparation of 3-[5′-(3,4-bis(hydroxymethyl)benzyloxy)-2′-ethyl-2-propylbiphenyl-4-yl]pentan-3-ol | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2009-12-29 | — | — | US | claimed |
| US-20070282136-A1 | Preparation of 3-[5'-(3,4-bis(hydroxymethyl)benzyloxy)-2'-ethyl-2-propylbiphenyl-4-yl]pentan-3-ol | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-12-06 | — | — | US | claimed |
| CN-116003770-A | Perfluoro polyether phosphate compound and preparation method and application thereof | 湖南柯盛新材料有限公司 | 2023-04-25 | — | — | CN | disclosed |
| WO-2022268066-A1 | PROTEIN DEGRADATION AGENT | 苏州开拓药业股份有限公司 | 2022-12-29 | — | — | WO | disclosed |
| EP-4051674-A1 | BIFUNCTIONAL COMPOUNDS FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2022-09-07 | — | — | EP | disclosed |
| CN-114728936-A | Bifunctional compounds for the treatment of cancer | 豪夫迈·罗氏有限公司 | 2022-07-08 | — | — | CN | disclosed |
| WO-2021083949-A1 | BIFUNCTIONAL COMPOUNDS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2021-05-06 | — | — | WO | disclosed |
| US-10449168-B2 | Potent phthalate inhibitors of aspartate N-acetyltransferase and selective aspartate pathway inhibitors | THE UNIVERSITY OF TOLEDO (US) | 2019-10-22 | — | — | US | disclosed |
| US-20180250252-A1 | POTENT PHTHALATE INHIBITORS OF ASPARTATE N-ACETYLTRANSFERASE AND SELECTIVE ASPARTATE PATHWAY INHIBITORS | THE UNIVERSITY OF TOLEDO (US) | 2018-09-06 | — | — | US | disclosed |
| WO-2017040376-A1 | POTENT PHTHALATE INHIBITORS OF ASPARTATE N-ACETYLTRANSFERASE AND SELECTIVE ASPARTATE PATHWAY INHIBITORS | THE UNIVERSITY OF TOLEDO (US) | 2017-03-09 | — | — | WO | disclosed |
| WO-1998005327-A1 | SUBSTITUTED AROMATIC COMPOUNDS | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1998-02-12 | — | — | WO | disclosed |
| EP-0369733-B1 | Fluorescent indicator dyes for alkali metal cations, their preparation and use | UNIV CALIFORNIA (US) | 1996-02-21 | — | — | EP | disclosed |
| US-5134232-A | Diagnosis; concentration in blood | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1992-07-28 | — | — | US | disclosed |
| EP-0369733-A2 | Fluorescent indicator dyes for alkali metal cations, their preparation and use | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1990-05-23 | — | — | EP | disclosed |
| US-4753962-A | HYPOGLYCEMIC, ANTIOBESITY AGENT | BEECHAM GROUP P.L.C. (GB) | 1988-06-28 | — | — | US | disclosed |
| US-4654371-A | ANTI-OBESITY, HYPOGLYCEMIA AGENTS | BEECHAM GROUP P.L.C. (GB) | 1987-03-31 | — | — | US | disclosed |
| US-4478849-A | HYPERGLYCEMIC AGENTS | BEECHAM GROUP LIMITED (GB) | 1984-10-23 | — | — | US | disclosed |
| EP-0006735-B1 | SECONDARY AMINES, THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE | BEECHAM GROUP PLC (GB) | 1983-06-15 | — | — | EP | disclosed |
| EP-0006735-A1 | Secondary amines, their preparation, pharmaceutical compositions containing them and their use | BEECHAM GROUP PLC (GB) | 1980-01-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10449168-B2 | Potent phthalate inhibitors of aspartate N-acetyltransferase and selective aspartate pathway inhibitors | NAT1, SAT1, NAALAD2 | ALDH1A1 104/4885GAA 343/4885KDM4E 2034/4885 |
| US-20180250252-A1 | POTENT PHTHALATE INHIBITORS OF ASPARTATE N-ACETYLTRANSFERASE AND SELECTIVE ASPARTATE PATHWAY INHIBITORS | NAT1, SAT1, NAALAD2 | ALDH1A1 104/4885GAA 343/4885KDM4E 2034/4885 |
| US-20070282136-A1 | Preparation of 3-[5'-(3,4-bis(hydroxymethyl)benzyloxy)-2'-ethyl-2-propylbiphenyl-4-yl]pentan-3-ol | PARP2, CYP4B1, CYP8B1 | ALDH1A1 550/4885GAA 3624/4885KDM4E 1198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.